Carried miR-125a can be targeted to bind HDAC1 and downregulate ET-1, thereby inhibiting mesangial hyperplasia and renal fibrosis, promoting cell apoptosis, inhibiting DN progression, and relieving symptoms. Here, EDN1 is linked to renal fibrosis.